A number of other equities research analysts have also weighed in on the stock. Guggenheim started coverage on shares of Heron Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $24.00 target price on the stock. Northland Securities began coverage on shares of Heron Therapeutics in a research report on Thursday, August 6th. They set a “buy” rating and a $35.00 target price for the company. SVB Leerink reduced their target price on shares of Heron Therapeutics from $26.00 to $19.00 and set an “outperform” rating for the company in a research report on Tuesday, June 30th. Finally, Stifel Nicolaus reissued a “buy” rating on shares of Heron Therapeutics in a research report on Tuesday, September 8th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Heron Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $30.44.
Heron Therapeutics stock opened at $16.28 on Friday. The business has a 50 day moving average price of $15.13 and a two-hundred day moving average price of $15.69. Heron Therapeutics has a 12 month low of $9.60 and a 12 month high of $26.81.
Several institutional investors and hedge funds have recently bought and sold shares of HRTX. First Trust Advisors LP boosted its holdings in shares of Heron Therapeutics by 6.1% in the first quarter. First Trust Advisors LP now owns 75,331 shares of the biotechnology company’s stock valued at $1,841,000 after acquiring an additional 4,335 shares during the period. UBS Group AG grew its position in Heron Therapeutics by 27.2% during the 1st quarter. UBS Group AG now owns 125,320 shares of the biotechnology company’s stock worth $1,471,000 after acquiring an additional 26,784 shares during the last quarter. Arizona State Retirement System bought a new stake in Heron Therapeutics during the 1st quarter worth approximately $236,000. New York State Common Retirement Fund grew its position in Heron Therapeutics by 4.5% during the 1st quarter. New York State Common Retirement Fund now owns 184,328 shares of the biotechnology company’s stock worth $2,164,000 after acquiring an additional 7,894 shares during the last quarter. Finally, Rhumbline Advisers grew its position in Heron Therapeutics by 4.0% during the 1st quarter. Rhumbline Advisers now owns 117,716 shares of the biotechnology company’s stock worth $1,382,000 after acquiring an additional 4,489 shares during the last quarter. Institutional investors and hedge funds own 96.49% of the company’s stock.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.